New products push Dainippon Sumitomo to growth
This article was originally published in Scrip
The launch of two new drugs helped Dainippon Sumitomo Pharma(DSP) ride out the general April price cut and falling sales of its main product in Japan in the first half to September 30th, when the firm's total consolidated net sales rose by 4% to ¥134.4 billion ($1.36 billion).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.